Gil Rabinovici's guest appearances

Gil Rabinovici

NEJM Interviews

GeriPal

Linda Fried

Hilary Seligman

Aaron Kesselheim

Melissa Wachterman

Keren Ladin

Amy Kind

David Reuben

Scott Halpern

Robert Truog

Mark Hall

George Church

David Hunter

Vivian Lee

George Annas

Louise Aronson

OwlTail

Dr. Gil Rabinovici is a professor of neurology at the University of California, San Francisco. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. G.D. Rabinovici. Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab. N Engl J Med 2021;385:771-774. G.C. Alexander and Others. Revisiting FDA Approval of Aducanumab. N Engl J Med 2021;385:769-771.

NEJM Interview: Dr. Gil Rabinovici on the FDA’s controversial approval of a new treatment for Alzheimer’s disease.

There are no currently approved disease modifying drugs for Alzheimer's disease, but in a couple months that may change.   In July of 2021, the FDA will consider approval of a human monoclonal antibody called Aducanumab for the treatment of Alzheimer's disease.  If approved, it will not only make this drug the defacto standard of care for Alzheimer's disease, but will create a monumental shift in the usage of other currently limited diagnostic tests, including Amyloid PET scans and other biomarkers. On today's podcast, we talk about all things Amyloid, including Aducanumab and Amyloid PET scans with Gil Rabinovici.  Dr. Rabinovici is the Edward Fein and Pearl Landrith Endowed Professor in Memory &amp; Aging at UCSF.    I could talk to Gil all day long, but we try to fit all of these topics in this jam-packed podcast:  The heterogeneity of dementia and potentially Alzheimer's disease Where are we now with disease modifying treatments for Alzheimer’s disease The Role of Amyloid PET scans and other biomarkers both now and in the future The wild story Aducanumab and the controversy surrounding its pending FDA approval 

There are no currently approved disease modifying drugs for Alzheimer's disease, but in a couple months that may change.   In July of 2021, the FDA will consider approval of a human monoclonal antibody called Aducanumab for the treatment of Alzheimer's disease.  If approved, it will not only make this drug the defacto standard of care for Alzheimer's disease, but will create a monumental shift in the usage of other currently limited diagnostic tests, including Amyloid PET scans and other biomarkers. On today's podcast, we talk about all things Amyloid, including Aducanumab and Amyloid PET scans with <a href="https://memory.ucsf.edu/people/gil-rabinovici-md" rel="nofollow" target="_blank">Gil Rabinovici</a>.  Dr. Rabinovici is the Edward Fein and Pearl Landrith Endowed Professor in Memory &amp; Aging at UCSF.    I could talk to Gil all day long, but we try to fit all of these topics in this jam-packed podcast: <ul> <li>The heterogeneity of dementia and potentially Alzheimer's disease</li> <li>Where are we now with disease modifying treatments for Alzheimer’s disease</li> <li>The Role of Amyloid PET scans and other biomarkers both now and in the future</li> <li>The wild story Aducanumab and the controversy surrounding its pending FDA approval</li> </ul>

All things Amyloid, including Aducanumab and Amyloid PET scans with Gil Rabinovici